exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087934 RNA Name: hsa-miR-218-5p RNA Type: miRNA Chromosome: chr5 Starnd: - Coordinate: Start Site(bp): 168768211 End Site(bp): 168768231 External Links: hsa-miR-218-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ABI2 chr2 203328239 203447728 + ADCY9 chr16 3953387 4116442 - CPA4 chr7 130293134 130324180 + GRK2 chr11 67266473 67286556 + IGF2 chr11 2129112 2141238 - LCLAT1 chr2 30447226 30644225 + LIN28B chr6 104936616 105083332 + OXSR1 chr3 38165089 38255484 + PARD6B chr20 50731580 50756795 + PRRC1 chr5 127517609 127555089 + RBBP9 chr20 18486540 18497225 - THUMPD1 chr16 20702816 20742084 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000798 chr17 65941524 65944422 + hsa_circ_0000155 chr1 168007608 168014465 + hsa_circ_0001452 chr4 153562079 153574079 - hsa_circ_0001860 chr9 37126308 37126939 + hsa_circ_0001146 chr20 34241449 34246936 - hsa_circ_0000799 chr17 65941524 65972074 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC004069.1 chr4 105137280 105140619 - AC021092.1 chr19 44103007 44113183 - AC125257.1 chr17 41848518 41851447 - ADAMTSL4-AS1 chr1 150560202 150574552 - KCNQ1OT1 chr11 2608328 2699994 - NEAT1 chr11 65422774 65445540 + OIP5-AS1 chr15 41283990 41309737 + PSMA3-AS1 chr14 58265365 58298134 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.